Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Genmab A/S

    NASDAQ: GMAB · Real-Time Price · USD
    21.48
    0.55 (2.63%)
    At close: May 02, 2025, 3:59 PM
    21.68
    0.91%
    After-hours: May 02, 2025, 05:21 PM EDT
    2.63%
    Bid 20.9
    Market Cap 13.54B
    Revenue (ttm) 21.53B
    Net Income (ttm) 7.84B
    EPS (ttm) 1.85
    PE Ratio (ttm) 11.61
    Forward PE 1.51
    Analyst Buy
    Ask 21.68
    Volume 1,310,274
    Avg. Volume (20D) 1,486,743
    Open 21.61
    Previous Close 20.93
    Day's Range 21.34 - 21.66
    52-Week Range 17.23 - 30.41
    Beta 0.96

    About GMAB

    Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Jun 1, 2009
    Employees 2,682
    Stock Exchange NASDAQ
    Ticker Symbol GMAB
    Website https://www.genmab.com
    Full Company Profile

    Analyst Forecast

    According to 9 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 90.83% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +2.65%
    Genmab A/S shares are trading higher after the com... Unlock content with Pro Subscription
    1 month ago
    -8.95%
    Genmab shares are trading lower after Johnson & Johnson decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not pursue further clinical development.
    news image

    3 days ago · businesswire.com

    Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food a...

    news image

    2 weeks ago · zacks.com

    GMAB or RGEN: Which Is the Better Value Stock Right Now?

    Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value...

    news image

    2 weeks ago · zacks.com

    Should Value Investors Buy Genmab (GMAB) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

    news image

    2 weeks ago · seekingalpha.com

    Genmab's Outlook Beyond Darzalex's Patent Cliff

    Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DAR...

    news image

    1 month ago · businesswire.com

    TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug ...

    news image

    1 month ago · benzinga.com

    Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

    The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S'  GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer c...

    news image

    1 month ago · businesswire.com

    TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of adva...

    news image

    1 month ago · businesswire.com

    Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational fola...

    news image

    1 month ago · seekingalpha.com

    Genmab: GEN3014's Demise And Implications For The HexaBody Platform

    Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 fur...

    news image

    1 month ago · businesswire.com

    Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop,...

    Add to Watchlist